US President Donald Trump has signed an executive order that aims to reduce high prescription drug prices – but its details ...

The discontinuation rate due to side effects was 6.1% for Zepbound and 8% for ... saying it would align US drug prices with ...

US drug prices are up to five times higher than in other developed nations. Trump's order requires US drug prices to align ...

Traders should observe LLY’s price action for signals that may influence short-term crypto volatility ... and regulatory scrutiny surrounding weight-loss drugs, a key growth area for Eli Lilly.

A bold move by US President Donald Trump to slash the cost of prescription drugs in America has sent shockwaves through the ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The discontinuation rate due to side effects was 6.1% for Zepbound and 8% for ... saying it would align US drug prices with the lowest-paying country. Eli Lilly’s stock has declined 5.6% so far in ...

Eli Lilly (LLY) shares take a dip after Politico reports that President Trump will sign a new executive order around drug ...

Eli Lilly and Company ( NYSE: LLY) BofA Securities 2025 Health Care Conference Call May 15, 2025 11:40 AM ET Lucas Montarce - CFO Mike Czapar - SVP, IR ...